Sept 22 (Reuters) - The weight-loss drug market is booming, with biotech firms racing to capture a slice of the fast-growing sector dominated by Novo Nordisk and Eli Lilly. Analysts expect the ...
The San Diego company's flexible dosing results could carve out real market share in the obesity drug race.
In an early human trial, Eli Lilly's eloralintide helped people lose up to 20% of their body weight. Reading time 3 minutes The race to develop the next generation of weight loss drugs has taken an ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Novo Nordisk is losing to Eli Lilly in the fiercely competitive weight loss market. But one of the company's mid-stage assets could help it remain a key player. Is there any hope left for the ...
Novo Nordisk's semaglutide, the active ingredient in Wegovy, mimics the action of the GLP-1 hormones, which play a role in regulating insulin and satiety. Wegovy is effective enough, but the company's ...
The news: Structure Therapeutics’ experimental obesity pill led to an average 12.1% weight loss after 36 weeks on a 120 mg daily dose, according to new mid-stage clinical trial data. Participants on a ...
InvestorsHub on MSN
Novo Nordisk considers acquisitions to expand weight-loss drug pipeline as competition intensifies
Novo Nordisk (NYSE:NVO) is considering acquisitions to strengthen its weight-loss drug pipeline and expand into related therapeutic areas as competition increases, Chief Executive Mike Doustdar said ...
Novo Nordisk's clinical setback elevates Viking's VK2735 in obesity drug race. Viking holds $706M cash, plans Phase 3 oral trial for 2026 after stock surges 11%. A recent shift in the competitive ...
Just one day after two closely watched studies failed to show that Novo Nordisk's oral GLP-1 semaglutide slows the progression of Alzheimer's disease, the company reported encouraging phase 2 results ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results